MedTrace Logo

MRI and Early Decision-making in Chemotherapy for Breast Cancer

NCT02449824 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-11-13

No results posted yet for this study

Summary

Firstly, the investigators aim to show that breast tumour blood flow, measured as part of a standard MRI examination, decreases at the earliest stage of neoadjuvant chemotherapy in those patients who go on to respond to treatment. Importantly, the investigators will also show that blood flow does not decrease in those patients who fail to respond.

Secondly, the investigators will test whether the decrease in tumour blood flow over the whole course of neoadjuvant chemotherapy can predict the response of the tumour measured at the time of surgery.

Conditions

  • Breast Neoplasms

Interventions

OTHER

magnetic resonance imaging

early MRI

Sponsors & Collaborators

  • University of Leeds

    lead OTHER

Principal Investigators

  • David L Buckley, PhD · University of Leeds

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02449824 on ClinicalTrials.gov